These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2145067)

  • 1. An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy.
    Rosse RB; Schwartz BL; Leighton MP; Davis RE; Deutsch SI
    Clin Neuropharmacol; 1990 Aug; 13(4):348-54. PubMed ID: 2145067
    [No Abstract]   [Full Text] [Related]  

  • 2. An NMDA intervention strategy in schizophrenia with "low-dose" milacemide.
    Rosse RB; Schwartz BL; Davis RE; Deutsch SI
    Clin Neuropharmacol; 1991 Jun; 14(3):268-72. PubMed ID: 1829980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia.
    Coyle JT; Tsai G
    Int Rev Neurobiol; 2004; 59():491-515. PubMed ID: 15006500
    [No Abstract]   [Full Text] [Related]  

  • 4. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia.
    Herting RL
    Ann N Y Acad Sci; 1991; 640():237-40. PubMed ID: 1837978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease and milacemide.
    Youdim MB
    Mov Disord; 1994 Sep; 9(5):585-6. PubMed ID: 7990857
    [No Abstract]   [Full Text] [Related]  

  • 6. Glycine agonists: what can they teach us about schizophrenia?
    Farber NB; Newcomer JW; Olney JW
    Arch Gen Psychiatry; 1999 Jan; 56(1):13-7. PubMed ID: 9892251
    [No Abstract]   [Full Text] [Related]  

  • 7. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
    Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
    Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
    Coyle JT; Tsai G; Goff D
    Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
    Anand A; Charney DS; Oren DA; Berman RM; Hu XS; Cappiello A; Krystal JH
    Arch Gen Psychiatry; 2000 Mar; 57(3):270-6. PubMed ID: 10711913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milacemide therapy for Parkinson's disease.
    Giuffra ME; Sethy VH; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993; 8(1):47-50. PubMed ID: 8380487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.
    Chaves C; Marque CR; Trzesniak C; Machado de Sousa JP; Zuardi AW; Crippa JA; Dursun SM; Hallak JE
    Braz J Med Biol Res; 2009 Nov; 42(11):1002-14. PubMed ID: 19855900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.
    Malhotra AK; Adler CM; Kennison SD; Elman I; Pickar D; Breier A
    Biol Psychiatry; 1997 Oct; 42(8):664-8. PubMed ID: 9325559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of negative symptoms in schizophrenia by glycine.
    Javitt DC; Zylberman I; Zukin SR; Heresco-Levy U; Lindenmayer JP
    Am J Psychiatry; 1994 Aug; 151(8):1234-6. PubMed ID: 8037263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-cycloserine added to clozapine for patients with schizophrenia.
    Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
    Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and electrophysiological effects of D-serine in a schizophrenia patient positive for anti-N-methyl-D-aspartate receptor antibodies.
    Heresco-Levy U; Durrant AR; Ermilov M; Javitt DC; Miya K; Mori H
    Biol Psychiatry; 2015 Mar; 77(6):e27-9. PubMed ID: 25442007
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo.
    Bressan RA; Erlandsson K; Stone JM; Mulligan RS; Krystal JH; Ell PJ; Pilowsky LS
    Biol Psychiatry; 2005 Jul; 58(1):41-6. PubMed ID: 15992521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Milacemide enhances memory storage and alleviates spontaneous forgetting in mice.
    Quartermain D; Nuygen T; Sheu J; Herting RL
    Pharmacol Biochem Behav; 1991 May; 39(1):31-5. PubMed ID: 1833781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
    Krystal JH; Karper LP; Seibyl JP; Freeman GK; Delaney R; Bremner JD; Heninger GR; Bowers MB; Charney DS
    Arch Gen Psychiatry; 1994 Mar; 51(3):199-214. PubMed ID: 8122957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.